fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

European Commission approves Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ stage III Hodgkin Lymphoma in combination with AVD chemotherapy – Takeda

Written by | 27 Oct 2023

Takeda announced that the European Commission (EC) approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage… read more.

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer

Written by | 27 Jul 2022

Treatment advances have improved the survival of individuals with Hodgkin lymphoma (HL)—a type of cancer that affects the lymphatic system—but therapies can increase patients’ risk of developing heart… read more.

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma

Written by | 16 Jul 2022

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma,… read more.

Keytruda monotherapy is EU approved for adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma – Merck Inc

Written by | 31 Mar 2021

Merck announced that the European Commission (EC) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients aged… read more.

Merck Inc. receives positive CHMP opinion for expanded approval of Keytruda in certain patients with relapsed or refractory classical Hodgkin lymphoma

Written by | 17 Feb 2021

Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an expanded… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.